dc.creator | Caldas, María | es |
dc.creator | Pérez-Aisa, Ángeles | es |
dc.creator | Castro Fernández, Manuel | es |
dc.creator | Bujanda, Luis | es |
dc.creator | Lucendo, Alfredo J. | es |
dc.creator | Rodrigo, Luis | es |
dc.creator | Pabón Carrasco, Manuel | es |
dc.creator | Gisbert, Javier P. | es |
dc.date.accessioned | 2022-09-02T15:01:02Z | |
dc.date.available | 2022-09-02T15:01:02Z | |
dc.date.issued | 2020-12-25 | |
dc.identifier.citation | Caldas, M., Pérez-Aisa, Á., Castro Fernández, M., Bujanda, L., Lucendo, A.J., Rodrigo, L.,...,Gisbert, J.P. (2020). European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics, 10 (1), 1-15. | |
dc.identifier.issn | 2079-6382 | es |
dc.identifier.uri | https://hdl.handle.net/11441/136651 | |
dc.description.abstract | The management of Helicobacter pylori infection has to rely on previous local effectiveness
due to the geographical variability of antibiotic resistance. The aim of this study was to
evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical
prescription is recommended. A multicentre prospective non-interventional registry of the
clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was
developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively
and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor
(PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included,
and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day
bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day
bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day
non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies.
Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple
quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple
schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness,
respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration
and higher acid inhibition were associated with higher effectiveness. “Optimized” H. pylori therapies
achieve over 90% success in Spain. | es |
dc.format | application/pdf | es |
dc.format.extent | 15 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Antibiotics, 10 (1), 1-15. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Helicobacter pylori | es |
dc.subject | Treatment | es |
dc.subject | First-line | es |
dc.subject | Second-line | es |
dc.subject | Spain | es |
dc.title | European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Enfermería | es |
dc.relation.publisherversion | https://www.mdpi.com/2079-6382/10/1/13 | es |
dc.identifier.doi | 10.3390/antibiotics10010013 | es |
dc.journaltitle | Antibiotics | es |
dc.publication.volumen | 10 | es |
dc.publication.issue | 1 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 15 | es |